A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. We have proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. We are also developing complementary imaging diagnostics that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This theranostic approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity. Our neuroendocrine tumor (VMT-α-NET), melanoma (VMT01) and solid tumor (PSV359) programs are in Phase 1/2a imaging and therapy trials in the U.S.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | 11M | 10M |
| Net Income | -103M | -103M | -79M | -47M | -11M | -3.4M |
| EPS | $-1.40 | $-1.40 | $-1.23 | $-17.40 | $-0.80 | $-0.30 |
| Free Cash Flow | -95M | -95M | -73M | -38M | -11M | -3.2M |
| ROIC | -49.9% | -41.2% | -27.1% | -60.5% | -19.7% | -4.9% |
| Gross Margin | - | - | - | - | 42.8% | 50.9% |
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.03 | 0.00 | - |
| Dividends/Share | $0.00 | - | - | - | - | $0.00 |
| Operating Income | -114M | -114M | -91M | -41M | -8.7M | -3.4M |
| Operating Margin | 0.0% | - | - | - | -80.3% | -34.3% |
| ROE | -49.8% | -41.4% | -27.3% | -61.9% | -19.7% | - |
| Shares Outstanding | 74M | 74M | 64M | 7M | 59M | 11M |
Perspective Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 46.9%.
Perspective Therapeutics, Inc. (CATX) has a 5-year average return on invested capital (ROIC) of -30.7%. This is below average and may indicate limited pricing power.
Perspective Therapeutics, Inc. (CATX) has a market capitalization of $320M. It is classified as a small-cap stock.
Perspective Therapeutics, Inc. (CATX) does not currently pay a regular dividend.
Perspective Therapeutics, Inc. (CATX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Perspective Therapeutics, Inc. (CATX) generated $-95 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Perspective Therapeutics, Inc. (CATX) has a debt-to-equity ratio of 0.02. This indicates a conservatively financed balance sheet.
Perspective Therapeutics, Inc. (CATX) reported earnings per share (EPS) of $-1.40 in its most recent fiscal year.
Perspective Therapeutics, Inc. (CATX) has a return on equity (ROE) of -41.4%. A negative ROE may indicate losses or negative equity.
Perspective Therapeutics, Inc. (CATX) has a 5-year average gross margin of 46.9%. This indicates decent pricing power.
The Ledger Terminal provides 15 years of financial data for Perspective Therapeutics, Inc. (CATX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Perspective Therapeutics, Inc. (CATX) has a book value per share of $2.81, based on its most recent annual SEC filing.